Suven Life Sciences share news, announcements and annual reports
NSE: SUVENBSE: 530239Healthcare ServicesSmall Cap
Suven Life Sciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Oct 2003 on NSE
Last close ₹271.75up ₹12.90 (4.98%)BSE ₹271.75
Share price at the NSE close on 2 Nov 2026. Previous close ₹258.85.
2 Nov: open ₹260.10, high ₹275.50, low ₹256.30
52-week range of traded prices to 2 Nov 2026
₹124.11Low, 24 Mar 2026₹403.35High, 1 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹7,679 Cr806th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −100.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −63.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,18,38627.5% delivered
Suven Life Sciences share news and announcements
803 announcements, routine notices left out, newest first. Page 13 of 17.
Feb 2013
4 Feb · Board meeting
To consider, inter alia and to take on record the Un-audited Financial Results for the third quarter ended December 31, 2012.
Jan 2013
21 Jan · Management
Company's Director Dr. Martin Tolar has resigned from the Company's Board due to his preoccupation. He ceased to be Director of the Company w.e.f. January 16, 2013.
Dec 2012
Nov 2012
5 Nov · Board meeting
To consider, inter alia and to take on record the Un-audited Financial Results for the second quarter ended September 30, 2012.
Oct 2012
Sep 2012
Aug 2012
24 Aug · News Verification
News Verification : The media had reports that Suven Life Sciences Limited may collaborate with a pharma company. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Suven Life Sciences Limited has vide its letter inter-alia stated, "We deny this news and the company is not aware of the source of this information."14 Aug · Dividend
Board of Directors of the Company in its meeting held on August 14, 2012, has recommended dividend Re. 0.30 paise per equity share of face value of Re. 1/- each (30%) for the financial year ended March 31, 2012 the dividend will be paid on and from October 12, 2012, subject to the approval of Members in ensuing Annual General Meeting.14 Aug · Meeting
Company has fixed Book Closure dates for the Register of members and Share Transfer from September 19, 2012 to September 21, 2012 for the purpose of Annual General Meeting and Dividend Declaration. The Annual General Meeting of the Company will be held on September 27, 2012.14 Aug · Results
14 Aug · Results
6 Aug · Board meeting
To consider, inter alia and to take on record the following matters : (1) To consider and approve the Audited Annual Accounts for the year ended March 31, 2012; (2) To recommend dividend for the financial year ended March 31, 2012, if any; (3) To announce Book Closure for the purpose of AGM; (4) To consider and take on record the Un-audited Financial Results for the first quarter ended June 30, 2012.
Jul 2012
May 2012
4 May · Updates
Apr 2012
25 Apr · Board meeting
To consider, inter alia and to take on record the Un-audited Financial Results for the quarter ended March 31, 2012.
Feb 2012
Jan 2012
31 Jan · Board meeting
W.e.f. December 31, 2011, Suven Nishtaa Pharma Pvt. Ltd. has become a wholly owned subsidiary company of Suven Life Sciences Limited. Further the Company has informed that the Board of Directors of the Company at its meeting held on January 31, 2012, inter alia, has given its consent for the amalgamation of the said wholly owned subsidiary - Suven Nishtaa Pharma Private Limited with the holding Company - Suven Life Sciences Limited, subject to the approval of the scheme by the Honble High Court of Andhra Pradesh. Consequent to the above, there will be no issue of shares pursuant to the merger, since the Company which is being proposed to be merged with the holding Company is a wholly owned subsidiary.23 Jan · Board meeting
To consider, inter alia and to take on record the Un-audited Financial Results for the third quarter ended December 31, 2011.
Dec 2011
Nov 2011
1 Nov · Updates
Oct 2011
21 Oct · Board meeting
To consider, inter alia and to take on record the Un-audited Financial Results for the second quarter ended September 30, 2011.
Sep 2011
Aug 2011
13 Aug · Results
1 Aug · Board meeting
To consider, inter alia and to take on record the Un-audited Financial Results for the first Quarter ended June 30, 2011.
Jul 2011
Jun 2011
1 Jun · Meeting
Company has fixed Book Closure dates for the Register of members and Share Transfer from August 03, 2011 to August 05, 2011 for the purpose of AGM & Dividend Declaration. The Annual General Meeting of the Company will be held on August 13, 2011.
May 2011
31 May · Dividend
Board of Directors of the Company at its meeting held on May 30, 2011, inter alia, has recommended dividend Re. 0.25 paisa per equity share of face value of Re. 1/- each (25%) for the financial year ended March 31, 2011 the dividend will be paid on and from August 28, 2011, subject to the approval of Members in ensuing Annual General Meeting.